These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26642338)

  • 1. Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.
    DeFilipp Z; Purcell M; Harris WA; Chandra DJ; Gleason C; Wrammert J; Sarantopoulos S; Waller EK
    Bone Marrow Transplant; 2016 Apr; 51(4):607-9. PubMed ID: 26642338
    [No Abstract]   [Full Text] [Related]  

  • 2. AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses.
    Gillissen MA; de Jong G; Levie SE; Yasuda E; Bakker AQ; Evers LM; Pals ST; Huisman C; van Helden PM; Spits H; Hazenberg MD
    Bone Marrow Transplant; 2016 Sep; 51(9):1245-8. PubMed ID: 27088384
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very late-onset reversible cardiomyopathy in patients with chronic GvHD.
    Kawano H; Tanaka H; Yamashita T; Hirata KI; Ishii S; Suzuki T; Wakahashi K; Kawano Y; Sada A; Minagawa K; Kawakami F; Itoh T; Baba A; Matsui T; Katayama Y
    Bone Marrow Transplant; 2015 Jun; 50(6):870-2. PubMed ID: 25798670
    [No Abstract]   [Full Text] [Related]  

  • 5. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
    Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.
    Vendramin A; Gimondi S; Bermema A; Longoni P; Rizzitano S; Corradini P; Carniti C
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2049-55. PubMed ID: 25246295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease-single center experience.
    Klobuch S; Weber D; Holler B; Edinger M; Herr W; Holler E; Wolff D
    Ann Hematol; 2019 Oct; 98(10):2399-2405. PubMed ID: 31375860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
    Krejci M; Doubek M; Buchler T; Brychtova Y; Vorlicek J; Mayer J
    Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory/relapsed AML patients in NR status.
    Liu N; Ning HM; Hu LD; Jiang M; Xu C; Hu JW; Wang J; Li YH; Li BT; Lou X; Yang F; Chen JL; Su YF; Li M; Wang HY; Ren J; Feng YQ; Zhang B; Wang DH; Chen H
    Leuk Res; 2015 Dec; 39(12):1375-81. PubMed ID: 26530539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar outcomes of peripheral blood stem cells vs. bone marrow for human leukocyte antigen-matched unrelated donor transplantation in adult patients with acute myeloid leukemia using risk-adapted graft-versus-host disease prophylaxis.
    Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Eur J Haematol; 2014 Jul; 93(1):19-28. PubMed ID: 24527665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful treatment of refractory acute GVHD with mycophenolate mofetil after peripheral blood stem cell transplantation from the patient's one locus-mismatched mother].
    Miyoshi T; Kawano-Yamamoto C; Nagashima T; Nagai T; Komatsu N; Muroi K; Ozawa K
    Rinsho Ketsueki; 2003 Sep; 44(9):968-70. PubMed ID: 14577320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rash and GI symptoms on day +36.
    Weisdorf D
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1405-6. PubMed ID: 17950925
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.
    von Bonin M; Oelschlägel U; Radke J; Stewart M; Ehninger G; Bornhauser M; Platzbecker U
    Transplantation; 2008 Sep; 86(6):875-9. PubMed ID: 18813113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitor levels matter in treating chronic GVHD.
    van der Wagen L; Janssen J; Raijmakers R; Petersen E; de Witte M; de Jong N; Bellido M; Meijer E; Bär B; Jan Boelens J; Huitema A; Kuball J
    Bone Marrow Transplant; 2019 Jul; 54(7):1141-1144. PubMed ID: 30651587
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
    Michallet M; Socié G; Mohty M; Sobh M; Bay JO; Morisset S; Labussière-Wallet H; Tabrizi R; Milpied N; Bordigoni P; El-Cheikh J; Blaise D
    Exp Hematol; 2013 Feb; 41(2):127-33. PubMed ID: 23089183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.